This company has been acquired

NasdaqGS:ABMD - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2025	1,488	262	N/A	446	2
3/31/2024	1,265	226	N/A	360	3
3/31/2023	1,144	269	N/A	299	3
9/30/2022	1,074	267	217	251	N/A
6/30/2022	1,056	218	263	298	N/A
3/31/2022	1,032	137	250	285	N/A
12/31/2021	1,003	133	246	293	N/A
9/30/2021	974	149	233	282	N/A
6/30/2021	935	154	248	298	N/A
3/31/2021	848	226	221	275	N/A
12/31/2020	813	200	237	275	N/A
9/30/2020	803	208	246	285	N/A
6/30/2020	798	159	240	282	N/A
3/31/2020	841	203	271	315	N/A
12/31/2019	841	245	257	299	N/A
9/30/2019	820	221	243	284	N/A
6/30/2019	797	258	229	270	N/A
3/31/2019	769	259	208	252	N/A
12/31/2018	737	222	191	238	N/A
9/30/2018	690	190	155	220	N/A
6/30/2018	641	165	142	203	N/A
3/31/2018	594	112	137	193	N/A
12/31/2017	544	90	103	173	N/A
9/30/2017	505	92	93	151	N/A
6/30/2017	475	77	70	125	N/A
3/31/2017	445	52	65	115	N/A
12/31/2016	415	48	69	100	N/A
9/30/2016	386	43	69	92	N/A
6/30/2016	359	42	N/A	92	N/A
3/31/2016	330	38	N/A	77	N/A
12/31/2015	303	126	N/A	73	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABMD's earnings are forecast to decline over the next 3 years (-2.5% per year).

Earnings vs Market: ABMD's earnings are forecast to decline over the next 3 years (-2.5% per year).

High Growth Earnings: ABMD's earnings are forecast to decline over the next 3 years.

Revenue vs Market: ABMD's revenue (13.1% per year) is forecast to grow faster than the US market (6.9% per year).

High Growth Revenue: ABMD's revenue (13.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ABMD's Return on Equity is forecast to be low in 3 years time (15.1%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

This company has been acquired

Abiomed Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Price target increased to US$362

Price target decreased to US$313

Price target decreased to US$319

Abiomed, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Consensus forecasts updated

Consensus forecasts updated

Recent updates

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Abiomed, Inc. (NasdaqGS:ABMD).

Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP

Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index (USD)

Abiomed, Inc. Announces First Patients in the World Treated with Impella Rp Flex with Smartassist

Price target increased to US$362

Independent Director notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Abiomed, Inc. (NasdaqGS:ABMD) for $17.4 billion.

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

Abiomed (NASDAQ:ABMD) Has More To Do To Multiply In Value Going Forward

Abiomed, Inc. Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

The United States Food and Drug Administration Grants 510(k) Clearance for Impella Low Profile Sheath

Abiomed's Impella low profile sheath gets FDA clearance

Abiomed, Inc. to Report Q2, 2023 Results on Nov 01, 2022

Price target decreased to US$313

Abiomed: Correction Offers Good Buying Opportunity

Abiomed Announces Two Approvals from the U.S. Food and Drug Administration Related to Clinical Research of Impella Heart Pumps in Acute Myocardial Infarction Cardiogenic Shock Patients

U.S. FDA gives two approvals to Abiomed Impella heart pumps

What Does Abiomed, Inc.'s (NASDAQ:ABMD) Share Price Indicate?

Abiomed Announces Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

First quarter 2023 earnings: EPS exceeds analyst expectations

Abiomed, Inc. (NasdaqGS:ABMD) announces an Equity Buyback for $200 million worth of its shares.

Price target decreased to US$319

Abiomed FQ1 2023 Earnings Preview

Abiomed, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Returns On Capital At Abiomed (NASDAQ:ABMD) Have Stalled

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Abiomed's Profit Growth Slows On R&D, Sales Hold Strong Despite Shortages

Full year 2022 earnings: EPS exceeds analyst expectations

Abiomed, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Is Abiomed (NASDAQ:ABMD) A Risky Investment?

Independent Director recently sold US$1.2m worth of stock

Senior VP & COO exercised options and sold US$3.1m worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Abiomed, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Consensus forecasts updated

Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk

Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

Abiomed, Inc. Announces Regulators Grants Approvals for Impella Surgical Products

The Returns At Abiomed (NASDAQ:ABMD) Aren't Growing

These 4 Measures Indicate That Abiomed (NASDAQ:ABMD) Is Using Debt Safely

Abiomed, Inc. (NasdaqGS:ABMD) agreed to acquire all the assets and business from Sensera, Inc. for $7.5 million.

Independent Director recently sold US$5.1m worth of stock

Second quarter 2022 earnings released: EPS US$1.25 (vs US$1.38 in 2Q 2021)

Abiomed: Impella Will Continue To Drive Revenue Growth

Here's What To Make Of Abiomed's (NASDAQ:ABMD) Decelerating Rates Of Return

Independent Director notifies of intention to sell stock

Consensus forecasts updated

Chairman exercised options and sold US$8.0m worth of stock

First quarter 2022 earnings released: EPS US$1.38 (vs US$0.99 in 1Q 2021)

Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

At US$335, Is It Time To Put Abiomed, Inc. (NASDAQ:ABMD) On Your Watch List?

Abiomed’s Receives U.S. Food and Drug Administration Pre-Market Approval as Safe and Effective to Treat Acute Right Heart Failure for Up to 14 Days

Chairman exercised options and sold US$7.6m worth of stock

DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue

Abiomed, Inc. (NasdaqGS:ABMD) acquired Precardia Inc.

Abiomed acquires preCARDIA a company targeting acute heart failure

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Here's Why I Think Abiomed (NASDAQ:ABMD) Might Deserve Your Attention Today

Senior VP & COO exercised options and sold US$3.7m worth of stock

Boston Scientific’s new clinical trial can impact Abiomed: Raymond James

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Abiomed, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Abiomed FQ4 2021 Earnings Preview

Should You Investigate Abiomed, Inc. (NASDAQ:ABMD) At US$315?